Skip to main content
Thursday, 15 June 2023 11:31

Secretory IgA Levels among COVID-19 Patients

1Hind H. Enad, MSc. and 2Abbas S. Al-Mizraqchi, PhD
¹Department of Dentistry, Al-Hadi University College, Iraq, 2Department of Basic Science,
College of Dentistry, 
University of Baghdad, Iraq.
Corresponding author: Hind H. Enad
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


Received 14 October 2022.
Accepted for publication on March 22, 2023.
Published June 14, 2023.
Doi: https://doi.org/10.58827/703425eyjjim


Abstract
Background
Immune system of the body and the SARS-CoV-2 virus interact closely, causing a variety of clinical presentations of the COVID-19 disease. While innate immune responses may occasionally aid the disease progression, adaptive immune responses are crucial for eliminating the SARS-CoV-2 virus. Secretory IgA, commonly abbreviated as sIgA, is an antibody that plays an important role in the immune system by binding to the surface molecules of pathogenic microbes to inhibit adhesion and colonization. Objectives This study aims to determine Salivary IgA levels in COVID-19 patients as the principal antibody in saliva which acts as the first line of the defence system in the body and mediates a variety of protective functions. Materials and Methods A total of 84 samples were taken from adults subjected to a PCR test. These individuals were categorized as follows: the COVID-19 group, which is comprised of 42 patients, and the COVID-19 free group, which is comprised of 42 participants. The collection of unstimulated saliva was performed, and laboratory investigations were carried out to evaluate the levels of salivary IgA using a SIgA kit (IgA saliva ELISA) manufactured by LDN Company. Results sIgA levels were significantly different between the patient and control groups (p= 0.009), with the COVID-19 group having a lower mean value (94.03) and the COVID-19-free group having a higher mean value (134.96). Conclusion Mucosal immunity, including secretory IgA, plays an important role in host defence against respiratory pathogens, and our early data suggest it may do so in COVID-19. Salivary IgA, an accessible marker of mucosal immunity, may be a useful indicator of several key parameters including individual immune response, disease severity, clinical risk, and herd immunity. The noninvasive nature and ease of saliva collection facilitate its potential use as a biomarker for ongoing patient assessment and management. suggesting that it could be used as a reliable biological indicator of clinical vulnerability to respiratory tract infections.

Read full article PDF file

Read 418 times